Background: Thyroidectomized patients need variable doses of levothyroxine (LT4) to obtain target thyroid-stimulating hormone (TSH) levels. Individual feedback set-points have been hypothesized and the influence of several genes in the regulation of the pituitary-thyroid axis has been demonstrated. Objectives: We hypothesized that genetic variants of the TRHR gene could be associated with a different hypothalamo-pituitary sensitivity to thyroid hormone feedback. Methods: We retrospectively analyzed 84 thyroidectomized patients with no residual thyroid function and undetectable thyroglobulin levels. Patients were evaluated under LT4 resulting in TSH levels detectable but <0.5 μIU/ml. The two SNPs rs3134105 and rs3110040 were identified as informative markers of the TRHR gene. Genotyping was performed using high-resolution melting technology. Genotype distribution was compared between the patients and 99 euthyroid controls. Results: The selected SNPs were in linkage disequilibrium and only rs3134105 was further considered. A significant difference between the three possible genotypes for rs3134105 was found for TSH (p = 0.04) and free thyroxine (fT4)/TSH ratio (p = 0.02). Moreover, despite similar serum concentrations of free triiodothyronine (fT3) and fT4, carriers of at least one A allele of rs3134105 had significantly lower serum TSH levels (p = 0.01) as well as higher fT3/TSH (p = 0.01) and fT4/TSH ratios (p < 0.01). Conclusions: We demonstrated an association between serum TSH levels and discrete alleles of the TRHR gene in totally thyroidectomized patients under LT4 therapy. Therefore, the TRHR gene seems to be a determinant of hypothalamo-pituitary sensitivity to LT4.

Keywords:
TRHR, Hypothalamo-pituitary sensitivity, TSH suppression
1.
Verhaert N, Vander Poorten V, Delaere P, Bex M, Debruyne F: Levothyroxine replacement therapy after thyroid surgery. B-ENT 2006;2:129-133.
2.
Wiersinga WM: Thyroid hormone replacement therapy. Horm Res 2001;56(suppl 1):74-81.
3.
Jonklaas J: Sex and age differences in levothyroxine dosage requirement. Endocr Pract 2010;16:71-79.
4.
Sawin CT, Herman T, Molitch ME, London MH, Kramer SM: Aging and the thyroid. Decreased requirement for thyroid hormone in older hypothyroid patients. Am J Med 1983;75:206-209.
5.
Olubowale O, Chadwick DR: Optimization of thyroxine replacement therapy after total or near-total thyroidectomy for benign thyroid disease. Br J Surg 2006;93:57-60.
6.
Gordon MB, Gordon MS: Variations in adequate levothyroxine replacement therapy in patients with different causes of hypothyroidism. Endocr Pract 1999;5:233-238.
7.
Bach-Huynh T-G, Nayak B, Loh J, Soldin S, Jonklaas J: Timing of levothyroxine administration affects serum thyrotropin concentration. J Clin Endocrinol Metab 2009;94:3905-3912.
8.
Benvenga S, Bartolone L, Pappalardo MA, Pappalardo MA, Russo A, Lapa D, Giorgianni G, Saraceno G, Trimarchi F: Altered intestinal absorption of L-thyroxine caused by coffee. Thyroid 2008;18:293-301.
9.
Singh N, Singh PN, Hershman JM: Effect of calcium carbonate on the absorption of levothyroxine. JAMA 2000;283:2822-2825.
10.
Liel Y, Harman-Boehm I, Shany S: Evidence for a clinically important adverse effect of fiber-enriched diet on the bioavailability of levothyroxine in adult hypothyroid patients. J Clin Endocrinol Metab 1996;81:857-859.
11.
Centanni M, Gargano L, Canettieri G, Viceconti N, Franchi A, Delle Fave G, Annibale B: Thyroxine in goiter, Helicobacter pylori infection, and chronic gastritis. N Engl J Med 2006;354:1787-1795.
12.
Ain KB, Refetoff S, Fein HG, Weintraub BD: Pseudomalabsorption of levothyroxine. JAMA 1991;266:2118-2120.
13.
Mandel SJ, Brent GA, Larsen PR: Levothyroxine therapy in patients with thyroid disease. Ann Intern Med 1993;119:492-502.
14.
Biondi B, Filetti S, Schlumberger M: Thyroid-hormone therapy and thyroid cancer: a reassessment. Nat Clin Pract Endocrinol Metab 2005;1:32-40.
15.
Hansen PS, Brix TH, Sørensen TIA, Kyvik KO, Hegedüs L: Major genetic influence on the regulation of the pituitary-thyroid axis: a study of healthy Danish twins. J Clin Endocrinol Metab 2004;89:1181-1187.
16.
Yin X, Latif R, Bahn R, Tomer Y, Davies TF: Influence of the TSH receptor gene on susceptibility to Graves' disease and Graves' ophthalmopathy. Thyroid 2008;18:1201-1206.
17.
De Jong FJ, Peeters RP, den Heijer T, van der Deure WM, Hofman A, Uitterlinden AG, Visser TJ, Breteler MM: The association of polymorphisms in the type 1 and 2 deiodinase genes with circulating thyroid hormone parameters and atrophy of the medial temporal lobe. J Clin Endocrinol Metab 2007;92:636-640.
18.
Panicker V, Cluett C, Shields B, Murray A, Parnell KS, Perry JR, Weedon MN, Singleton A, Hernandez D, Evans J, Durant C, Ferrucci L, Melzer D, Saravanan P, Visser TJ, Ceresini G, Hattersley AT, Vaidya B, Dayan CM, Frayling TM: A common variation in deiodinase 1 gene DIO1 is associated with the relative levels of free thyroxine and triiodothyronine. J Clin Endocrinol Metab 2008;93:3075-3081.
19.
Peeters RP, van den Beld AW, Attalki H, Toor H, de Rijke YB, Kuiper GG, Lamberts SW, Janssen JA, Uitterlinden AG, Visser TJ: A new polymorphism in the type II deiodinase gene is associated with circulating thyroid hormone parameters. Am J Physiol Endocrinol Metab 2005;289:E75-E81.
20.
Torlontano M, Durante C, Torrente I, Crocetti U, Augello G, Ronga G, Montesano T, Travascio L, Verrienti A, Bruno R, Santini S, D'Arcangelo P, Dallapiccola B, Filetti S, Trischitta V: Type 2 deiodinase polymorphism (threonine 92 alanine) predicts L-thyroxine dose to achieve target thyrotropin levels in thyroidectomized patients. J Clin Endocrinol Metab 2008;93:910-913.
21.
Hoftijzer HC, Heemstra KA, Visser TJ, le Cessie S, Peeters RP, Corssmit EP, Smit JW: The type 2 deiodinase ORFa-Gly3Asp polymorphism (rs12885300) influences the set point of the hypothalamus-pituitary-thyroid axis in patients treated for differentiated thyroid carcinoma. J Clin Endocrinol Metab 2011;96:E1527-E1533.
22.
Peeters RP, van Toor H, Klootwijk W, de Rijke YB, Kuiper GG, Uitterlinden AG, Visser TJ: Polymorphisms in thyroid hormone pathway genes are associated with plasma TSH and iodothyronine levels in healthy subjects. J Clin Endocrinol Metab 2003;88:2880-2888.
23.
Lago-Lestón R, Iglesias MJ, San-José E, Areal C, Eiras A, Araújo-Vilar D, Lado-Abeal J, Domínguez-Gerpe L: Prevalence and functional analysis of the S107P polymorphism (rs6647476) of the monocarboxylate transporter 8 (SLC16A2) gene in the male population of north-west Spain (Galicia). Clin Endocrinol (Oxf) 2009;70:636-643.
24.
Van der Deure WM, Peeters RP, Visser TJ: Molecular aspects of thyroid hormone transporters, including MCT8, MCT10, and OATPs, and the effects of genetic variation in these transporters. J Mol Endocrinol 2010;44:1-11.
25.
Refetoff S, Murata Y, Mori Y, Janssen OE, Takeda K, Hayashi Y: Thyroxine-binding globulin: organization of the gene and variants. Horm Res 1996;45:128-138.
26.
Sørensen HG, van der Deure WM, Hansen PS, Peeters RP, Breteler MM, Kyvik KO, Sørensen TI, Hegedüs L, Visser TJ: Identification and consequences of polymorphisms in the thyroid hormone receptor α and β genes. Thyroid 2008;18:1087-1094.
27.
Hall R, Amos J, Garry R, Buxton RL: Thyroid-stimulating hormone response to synthetic thyrotropin-releasing hormone in man. Br Med J 1970;2:274-277.
28.
Bianco AC, Kim BW: Deiodinases: implications of the local control of thyroid hormone action. J Clin Invest 2006;116:2571-2579.
29.
Morley JE: Extrahypothalamic thyrotropin-releasing hormone (TRH) - its distribution and its functions. Life Sci 1979;25:1539-1550.
30.
Pettersson FH, Anderson CA, Clarke GM, Barrett JC, Cardon LR, Morris AP, Zondervan KT: Marker selection for genetic case-control association studies. Nat Protoc 2009;4:743-752.
31.
Tüttelmann F, Luetjens CM, Nieschlag E: Optimising workflow in andrology: a new electronic patient record and database. Asian J Androl 2006;8:235-241.
32.
Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JW, Wiersinga W: European Thyroid Cancer Taskforce. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 2006;154:787-803.
33.
Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Pacini F, Schlumberger M, Sherman SI, Steward DL, Tuttle RM: Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009;19:1167-1214.
34.
Barrett JC, Fry B, Maller J, Daly MJ: Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005;21:263-265.
35.
Matre V, Høvring PI, Orstavik S, Frengen E, Rian E, Velickovic Z, Murray-McIntosh RP, Gautvik KM: Structural and functional organization of the gene encoding the human thyrotropin-releasing hormone receptor. J Neurochem 1999;72:40-50.
© 2014 European Thyroid Association Published by S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.